Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females between 18 and 90 years of age, inclusive.~* Diagnosed with primary episode or first relapse of moderate C. difficile infection.~Received ≤24 hours of therapy effective for C. difficile infection prior to enrollment.~Exclusion Criteria:~* Severe C. difficile infection~* Expected to require more than 10 days of C. difficile infection treatment.~* More than one prior episode of C. difficile infection within the prior 3 months.~* Use of anti-peristaltic drugs (including tincture of opium, metoclopramide, loperamide),, cholestyramine, or colestipol~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- LFF571 (POC) (Type: EXPERIMENTAL): None
- Vancomycin (POC) (Type: ACTIVE_COMPARATOR): None
- LFF571 Dose level 1 (cohort 2) (Type: EXPERIMENTAL): None
- LFF571 Dose level 2 (cohort 2) (Type: EXPERIMENTAL): None
- LFF571 Dose level 3 (cohort 2) (Type: EXPERIMENTAL): None
- LFF571 Dose level 4 (cohort 2) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).